John T. Cavan
Net Worth

Last updated:

What is John T. Cavan net worth?

The estimated net worth of Mr. John T. Cavan is at least $3,250,777 as of 18 Feb 2021. He owns shares worth $777 as insider and has received compensation worth at least $3,250,000 in Hepion Pharmaceuticals, Inc..

What is the salary of John T. Cavan?

Mr. John T. Cavan salary is $406,250 per year as Chief Financial Officer in Hepion Pharmaceuticals, Inc..

How old is John T. Cavan?

Mr. John T. Cavan is 67 years old, born in 1958.

What stocks does John T. Cavan currently own?

As insider, Mr. John T. Cavan owns shares in one company:

Company Title Shares Price per share Total value
Hepion Pharmaceuticals, Inc. (HEPA) Chief Financial Officer 14,800 $0.05 $777

What does Hepion Pharmaceuticals, Inc. do?

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

HEPA logo
HEPA
Hepion Pharmaceuticals, Inc.
$0.05

John T. Cavan insider trading

Hepion Pharmaceuticals, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 10,000 $2 $20,000
Purchase
Common Stock 4,500 $1.62 $7,290
Purchase
Series C Convertible Preferred Stock 15 $1.55 $23
Purchase
Warrants 8,625 N/A N/A
Purchase
Common Stock 20,000 $0.65 $13,000

Hepion Pharmaceuticals key executives

Hepion Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:

  • Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D. (67) Pres, Chief Executive Officer & Director
  • Mr. John T. Cavan (67) Chief Financial Officer